LAG-3 as the third checkpoint inhibitor. [PDF]
Nat Immunol, 2023 Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor that is highly expressed by exhausted T cells. LAG-3 is a promising immunotherapeutic target, with more than 20 LAG-3-targeting therapeutics in clinical trials and a fixed-dose combination of anti-LAG-3 and anti-PD-1 now approved to treat unresectable or metastatic melanoma.
Aggarwal V, Workman CJ, Vignali DAA.
europepmc +4 more sources
Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements [PDF]
Biomarker ResearchTreatment based on immune checkpoint blockade has revolutionized cancer therapy. Despite the remarkable success achieved and the preclinical development of multiple checkpoint inhibitors targeting other checkpoints, only antibodies targeting the PD-1/PD ...
Alejandra Martínez-Pérez +4 more
doaj +4 more sources
Understanding LAG-3 Signaling [PDF]
International Journal of Molecular Sciences, 2021 Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions.
L. Chocarro +13 more
semanticscholar +5 more sources
LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
Biomedicines, 2023 One of the most important steps forward in the management of cancer was the discovery of immunotherapy. It has become an essential pillar in the treatment paradigm of cancer patients.
Rebecca Ibrahim +5 more
doaj +2 more sources
LAG-3: from molecular functions to clinical applications [PDF]
Journal for ImmunoTherapy of Cancer, 2020 To prevent the destruction of tissues owing to excessive and/or inappropriate immune responses, immune cells are under strict check by various regulatory mechanisms at multiple points.
Takumi Maruhashi +3 more
doaj +3 more sources
LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures [PDF]
OncoImmunology, 2020 Despite the success of immunotherapy using checkpoint blockade, many patients with solid tumors remain refractory to these treatments. In human cancer, the experimental options to investigate the specific effects of antibodies blocking inhibitory ...
Nicolas Gestermann +8 more
doaj +4 more sources
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. [PDF]
ImmunityLAG-3, TIM-3, and TIGIT comprise the next generation of immune checkpoint receptors being harnessed in the clinic. Although initially studied for their roles in restraining T cell responses, intense investigation over the last several years has started ...
Joller N, Anderson AC, Kuchroo VK.
europepmc +2 more sources
LAG-3 palmitoylation-inducing dysfunction of decidual CD4+T cells is associated with recurrent pregnancy loss [PDF]
Molecular MedicineRecurrent pregnancy loss (RPL) profoundly impacts not only the physical health but also the psychological well-being of women. Despite its profound effects, the underlying pathophysiological mechanisms of RPL remain largely elusive, with few discernible ...
Liyuan Cui +5 more
doaj +2 more sources
Dissociation of LAG-3 inhibitory cluster from TCR microcluster by immune checkpoint blockade [PDF]
Frontiers in ImmunologyLymphocyte activation gene (Lag)-3 is an inhibitory co-receptor and target of immune checkpoint inhibitor (ICI) therapy for cancer. The dynamic behavior of Lag-3 was analyzed at the immune synapse upon T-cell activation to elucidate the Lag-3 inhibitory ...
Akiko Hashimoto-Tane +7 more
doaj +2 more sources
The correlation between LAG-3 expression and the efficacy of chemoimmunotherapy in advanced biliary tract cancer [PDF]
Cancer Immunology, ImmunotherapyIn our previous phase II T1219 trial for advanced biliary tract cancer (ABTC), the combination of nivolumab with modified gemcitabine and S-1 exhibited promising efficacy, while the programmed-death-ligand-1 (PD-L1) expression did not predict ...
Cheng-Yu Tang +8 more
doaj +2 more sources